Forte Biosciences acquired by argenx for $77.00/share, ~$2.2B; delisting planned

Forte Biosciences, Inc.

Tender offer accepted 19,894,879 shares (~87.13% of outstanding) at $77.00/share cash.
Merger completed Aug 27, 2026; Forte is now a wholly owned subsidiary of argenx BV.
Total consideration ~$2.2B funded from argenx cash; covers options, RSUs, warrants.
All prior directors/officers replaced; new board includes Arjen Lemmen, Karl Gubitz, Malini Moorthy.
Company requested Nasdaq delisting and will file Form 15 to suspend SEC reporting.

item 2.01 item 3.01 item 3.03 item 5.01 item 5.02 item 5.03 item 9.01

Featured in Daily 8-K Digest

Selected #7 for 2026-08-27. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.